Furthermore, muscarinic receptor activation stimulated the putative PI 3-kinase and MAPK/ERK survival pathways, but these pathways do not appear to mediate the muscarinic effect on caspase inhibition.

3) Bristol Myers Squibb's Cobenfy (KarXT; xanomeline and trospium chloride), a dual M1/M4 muscarinic acetylcholine receptor agonist for schizophrenia and psychosis related to Alzheimer's disease.